Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Wondering what age you should start planning for retirement? Discover key insights that will help you prepare for a secure financial future.
25,645 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A notable stake from an experienced manager in a healthcare diagnostics stock signals a thoughtful, long term thesis....
Rivian has captured imaginations—and capital. But the next 12 months will test its ability to scale, control costs, a...
A large institutional stake in Enviri sparks questions about the company’s trajectory. This article breaks down what ...
A February market shock erased roughly $285B in software valuations, forcing a rethink of what truly drives software ...
Boone Capital just disclosed a fresh position in HealthEquity, raising questions about the stock's potential. This gu...
Astera Labs has captured investor attention with a strong rally. This article dives into the reasons behind the move,...
Tilray Brands is expanding beyond its cannabis roots into beverages and other segments. This article examines whether...
A major fund plowed into a top U.S. homebuilder with a $65 million stake, ahead of a rumored $47-per-share buyout. He...
Chase has cut credit-card limits for some customers with minimal usage, raising questions about credit-score impact a...
Policy shifts around president trump's drug pricing could squeeze pharma profits and shift stock dynamics. This guide...
York Space Systems stock jumped today as the company posted a revenue beat and improved growth indicators. This guide...